We are live on ! Find out more
OSIR

Osiris Therapeutics, Inc. Common Stock
OSIR

Delisted

OSIR was delisted on the 16th of April, 2019.

83 hedge funds and large institutions have $155M invested in Osiris Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 4

81% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 16

26% more funds holding

Funds holding: 6683 (+17)

14% more capital invested

Capital invested by funds: $135M → $155M (+$19.6M)

81% less call options, than puts

Call options by funds: $976K | Put options by funds: $5.15M

Holders
83
Holders Change
+17
Holders Change %
+25.76%
% of All Funds
2.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
29
Reduced
16
Closed
4
Calls
$976K
Puts
$5.15M
Net Calls
-$4.17M
Net Calls Change
+$2.66M

OSIR Hedge Fund Activity: Q1 2015 in Review

83 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q1 2015, worth a combined $155M — up 14% from $135M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new OSIR positions and 4 closed out — a net gain of 18 holders — while 29 added to existing stakes and 16 trimmed.

The largest buyer was Venator Capital Management, opening a new position worth an estimated $2.94M. The largest seller was Consonance Capital Management, cutting an estimated $8M.

  • 83 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q1 2015, up from 66 in Q4 2014.
  • Funds reported $155M of Osiris Therapeutics, Inc. Common Stock stock for Q1 2015, up 14% quarter-over-quarter.
  • 22 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q1 2015 and 4 closed out, a net change of +18 holders.
  • The largest Osiris Therapeutics, Inc. Common Stock buyer in Q1 2015 was Venator Capital Management, an estimated $2.94M added.
  • The largest Osiris Therapeutics, Inc. Common Stock seller in Q1 2015 was Consonance Capital Management, an estimated $8M sold.

Based on aggregated 13F filings for Q1 2015.